|
Session 23-Oral Abstracts
HIV Vaccines: The Path Forward
Thursday, 9:30 am-12 noon; Room 2004 |
| 9:30 am 74 |
RV 144 Update: Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thai Adults
Nelson Michael
Walter Reed Army Inst of Res, Silver Spring, MD, US |
| 10:00 am 75 |
Vaccine-induced Changes in Breakthrough HIV-1 Sequences from the Step Trial
Morgane Rolland*1, S Tovanabutra2, P Gilbert3, J Kim2, L Corey3, S Buchbinder4, M Robertson5, J McElrath3, F McCutchan2, J Mullins1, and the Step Trial Study Group
1Univ of Washington, Seattle, US; 2US Military HIV Res Prgm, Rockville, MD; 3Vaccine and Infectious Disease Inst, Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 4San Francisco Dept of Publ Hlth, CA, US; and 5Merck Res Labs, West Point, PA, US |
| 10:15 am 76 |
Factors Associated with Viral Rebound in HIV+ Subjects Receiving a Therapeutic HIV-1 gag Vaccine
Jonathan Li*1, C Brumme2, Z Brumme2, H Wang3, J Spritzler3, M Robertson4, M Lederman5, B Walker2, R Schooley6, D Kuritzkes1, and ACTG 5197 Study Team
1Brigham and Women’s Hosp, Boston, MA, US; 2Ragon Inst of Massachusetts Gen Hosp, Massachusetts Inst of Tech, and Harvard Univ, Cambridge, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Merck Res Labs, West Point, PA, US; 5Case Western Reserve Univ, Cleveland, OH, US; and 6Univ of California, San Diego, La Jolla, US |
| 10:30 am 77 |
A Phase I Double-blind Placebo-controlled Randomized Study of a Therapeutic Vaccine Using Autologous DC Loaded with Autologous HIV-1 in Untreated Patients with Asymptomatic Chronic HIV Infection
M Plana1, Felipe García*1, N Climent1, C Gil1, B Autran2, L Assoumou3, D Costagliola3, B Clotet4, J Gatell1, T Gallart1, and for DCV2/MANON07-ORVACS Study Group
1HIVACAT, Hosp Clin, Univ of Barcelona, Spain; 2INSERM UMRS945, Univ Paris 6 and Pierre and Marie Curie, Hosp Pitie-Salpetriere, France; 3INSERM U943, Univ Pierre and Marie Curie, Paris, France; and 4Fndn irsiCaixa, Hosp Univ Germans Trias i Pujol, Badalona, Spain |
| 10:45 am 78LB |
Optimal Priming of Poxvirus Vector-based HIV Vaccine Regimens Requires 3 DNA Injections: Results of the Randomized Multicentre EV03/ANRS Vac20 Phase I/II Trial
Y Levy1, K Ellefsen2, W Stöehr3, P-A Bart2, J-D Lelièvre1, O Launay4, H Wolf5, J Weber6, G Chêne7, and Giuseppe Pantaleo*2
1Ctr Hosp Univ Henri Mondor, Créteil, France; 2Ctr Hosp Univ Vaudois, Lausanne, Switzerland; 3Med Res Council Clin Trials Unit, London, UK; 4Ctr for Clin Investigation Vaccinology Cochin-Pasteur, Paris, France; 5Univ of Regensburg, Germany; 6Imperial Coll London, St Mary`s Hosp, UK; and 7INSERM U593, Bordeaux, France |
| 11:00 am 79LB |
Preclinical Studies on DNA/MVA Vaccines: Co-expressed GM-CSF, a Strong Adjuvant for Prevention of Infection
Harriet Robinson*1, L Lai2, D Montefiori3, P Kozlowski4, S Kwa2, M Siddiqui2, L Chennareddi2, L Wyatt5, B Moss5, and R Amara6
1GeoVax, Inc, Smyrna, GA, US; 2Yerkes Natl Primate Res Ctr, Atlanta, GA, US; 3Duke Univ Human Vaccine Inst, Durham, NC, US; 4Louisiana State Univ Hlth Sci Ctr, New Orleans, US; 5NIAID, NIH, Bethesda, MD, US; and 6Emory Vaccine Ctr, Atlanta, GA, US |
| 11:15 am 80LB |
Expansion in vivo of Naïve and Activated Treg in IL-2-treated HIV Patients
Laurence Weiss*1,2,3,4, F Letimier2, M Carriere1, S Maiella2, V Donkova-Petrini1, B Targat5, A Benecke5, L Rogge2, and Y Levy1,6
1INSERM U955, Creteil, France; 2Inst Pasteur, Paris, France; 3European Hosp Georges Pompidou, Paris, France; 4Univ Paris Descartes, France; 5Inst des Hautes Etudes Scientifiques, IRI CNRS USR3078, Bures sur Yvette, France; and 6Hosp Henri Mondor, Univ Paris 12, France |
| 11:30 am 81 |
Lentiviral Vector-based Anti-HIV-1 Vaccine Induces Strong T Cell and Antibody Responses in Macaques, with and without DNA Priming
Franck Lemiale*1, M Morrow2, L Shovlin1, N Korokhov1, D Weiner2, and L Humeau1
1VIRxSYS Corp, Gaithersburg, MD, US and 2Univ of Pennsylvania Sch of Med, Philadelphia, US |
| 11:45 am 82 |
Broad HIV Neutralizing Antibodies Can Be Elicited by the GBV-C Glycoprotein E2 and Neutralize HIV via a 2F5-like Mechanism
S Jung, H Wend, N Donhauser, K Eissmann, B Fleckenstein, and Heide Reil*
Univ Hosp Erlangen, Germany |
|
